FCCP (Trifluoromethoxy carbonylcyanide phenylhydrazone, Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone) is a potent uncoupler of oxidative phosphorylation in mitochondria that disrupts ATP synthesis by transporting protons across cell membranes.

FCCP (Trifluoromethoxy carbonylcyanide phenylhydrazone, Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone) is a potent uncoupler of oxidative phosphorylation in mitochondria that disrupts ATP synthesis by transporting protons across cell membranes.

FCCP (Trifluoromethoxy carbonylcyanide phenylhydrazone, Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone) is a potent uncoupler of oxidative phosphorylation in mitochondria that disrupts ATP synthesis by transporting protons across cell membranes.

FCCP (Trifluoromethoxy carbonylcyanide phenylhydrazone, Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone) is a potent uncoupler of oxidative phosphorylation in mitochondria that disrupts ATP synthesis by transporting protons across cell membranes.

A unique collection of 3621 drugs that are marketed around the world or have passed clinical phase 1 and can be used for high throughput screening (HTS) and high content screening (HCS).

A unique collection of 3621 drugs that are marketed around the world or have passed clinical phase 1 and can be used for high throughput screening (HTS) and high content screening (HCS).

A unique collection of 1746 approved drugs with potential anticancer activity used for high throughput screening(HTS) and high content screening(HCS).

A unique collection of 3109 approved drugs and API included in pharmacopoeia for high throughput screening (HTS) and high content screening (HCS).

A unique collection of 3109 approved drugs and API included in pharmacopoeia for high throughput screening (HTS) and high content screening (HCS).

FDI-6 (NCGC00099374) is an inhibitor of the Forkhead box protein M1 transcription factor (FOXM1) with IC50 of 22.5 μM.

FDI-6 (NCGC00099374) is an inhibitor of the Forkhead box protein M1 transcription factor (FOXM1) with IC50 of 22.5 μM.

FDI-6 (NCGC00099374) is an inhibitor of the Forkhead box protein M1 transcription factor (FOXM1) with IC50 of 22.5 μM.

FDL169 is a CFTR corrector that is designed to fix and restore the function of the defective CFTR protein.

FDL169 is a CFTR corrector that is designed to fix and restore the function of the defective CFTR protein.

Febantel (Rintal, Combotel, Oratel, Bay Vh 5757, Negabot Plus) is a prodrug that is metabolized to fenbendazole and oxfendazole, which are undoubtedly the active parasiticides.

Febuxostat (TMX 67, TEI-6720) is a selective xanthine oxidase inhibitor with Ki of 0.6 nM.

Febuxostat (TMX 67, TEI-6720) is a selective xanthine oxidase inhibitor with Ki of 0.6 nM.

Fedratinib (SAR302503, TG101348) is a selective inhibitor of JAK2 with IC50 of 3 nM in cell-free assays, 35- and 334-fold more selective for JAK2 versus JAK1 and JAK3. Fedratinib also inhibits FMS-like tyrosine kinase 3 (FLT3) and RET (c-RET) with IC50 of 15 nM and 48 nM, respectively. Fedratinib has potential antineoplastic activity. Fedratinib inhibits […]

Felbamate (Felbatol, ADD-03055,W-554) is an anticonvulsant drug used in the treatment of epilepsy; NMDAR antagonist.

Felodipine (CGH-869) is a selective L-type Ca2+ channel blocker with IC50 of 0.15 nM.

Felypressin-Acetate is a non-catecholamine vasoconstrictor that is chemically associated to vasopressin, the posterior pituitary hormone.

FEN1-IN-4 (FEN1 Inhibitor C2, JUN93587, Compound 2) is an inhibitor of human flap endonuclease-1 (hFEN1) with IC50 of 30 nM for hFEN1-336Δ.

Fenamic acid (N-Phenylanthranilic acid, 2-(Phenylamino)benzoic acid, 2-Anilinobenzoic acid, Diphenylamine-2-carboxylic acid) serves as a parent structure for several nonsteroidal anti-inflammatory drugs (NSAIDs), including mefenamic acid, tolfenamic acid, flufenamic acid, and meclofenamic acid.

Fenamic acid (N-Phenylanthranilic acid, 2-(Phenylamino)benzoic acid, 2-Anilinobenzoic acid, Diphenylamine-2-carboxylic acid) serves as a parent structure for several nonsteroidal anti-inflammatory drugs (NSAIDs), including mefenamic acid, tolfenamic acid, flufenamic acid, and meclofenamic acid.

Fenbendazole(Fenbendazol,Phenbendasol) is a broad spectrum benzimidazole anthelmintic used against gastrointestinal parasites with an IC50 of about 0.01 μg/mL.

Fenbufen (Lederfen, CL-82204) is an orally active phenylalkanoic derivative with anti-inflammatory, analgesic and antipyretic activity. It is a non-steroidal anti-inflammatory drug.

Fenchyl Alcohol is used as a flavoring agent to provide a pine, herbal, lemon, or floral taste to food and drink.

Fendiline hydrochloride is the hydrochloride salt form of Fendiline, which is an L-type calcium channel blocker and also a specific inhibitor of K-Ras plasma membrane targeting with no detectable effect on the localization of H- and N-Ras.

Fendiline hydrochloride is the hydrochloride salt form of Fendiline, which is an L-type calcium channel blocker and also a specific inhibitor of K-Ras plasma membrane targeting with no detectable effect on the localization of H- and N-Ras.

Fenebrutinib (GDC-0853) is a potent, selective, and non-covalent bruton’s tyrosine kinase (BTK) inhibitor with an Ki value of 0.91 nM for Btk with >100-fold selectivity over 3 off-targets (Bmx :153-fold, Fgr: 168-fold, Src:131-fold).

Fenebrutinib (GDC-0853) is a potent, selective, and non-covalent bruton’s tyrosine kinase (BTK) inhibitor with an Ki value of 0.91 nM for Btk with >100-fold selectivity over 3 off-targets (Bmx :153-fold, Fgr: 168-fold, Src:131-fold).

Fenebrutinib (GDC-0853) is a potent, selective, and non-covalent bruton’s tyrosine kinase (BTK) inhibitor with an Ki value of 0.91 nM for Btk with >100-fold selectivity over 3 off-targets (Bmx :153-fold, Fgr: 168-fold, Src:131-fold).

Fenipentol (1-phenylpentan-1-ol, 1-Phenyl-1-pentanol, 1-Phenylpentanol) is a member of benzenes and stimulates plasma secretion & exocrine pancreatic secretion.

Fenofibrate is a compound of the fibrate class and fibric acid derivative. Fenofibrate is a selective agonist of PPARα with EC50 of 30 μM. Fenofibrate binds to and inhibits cytochrome P450 epoxygenase (CYP)2C with IC50 of 0.2 μM, 0.7 μM and 9.7 μM for CYP2C19, CYP2B6 and CYP2C9, respectively. Fenofibrate induces autophagy.

Fenofibrate is a compound of the fibrate class and fibric acid derivative. Fenofibrate is a selective agonist of PPARα with EC50 of 30 μM. Fenofibrate binds to and inhibits cytochrome P450 epoxygenase (CYP)2C with IC50 of 0.2 μM, 0.7 μM and 9.7 μM for CYP2C19, CYP2B6 and CYP2C9, respectively. Fenofibrate induces autophagy.

Fenofibric acid (NSC 281318, Trilipix, FNF acid) is a fibrate that acts as a lipid-lowering agent, decreasing low-density lipoprotein cholesterol and triglycerides.

Fenofibric acid (NSC 281318, Trilipix, FNF acid) is a fibrate that acts as a lipid-lowering agent, decreasing low-density lipoprotein cholesterol and triglycerides.